49 results on '"Bigenwald, Camille"'
Search Results
2. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology
3. Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders
4. Supplementary Figure S3 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
5. Supplementary Table S4 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
6. Data from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
7. Supplementary Table Legends from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
8. Histiocytic disorders
9. CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
10. When monoclonal gammopathy‐associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes
11. Light shed from the gut in large B-cell lymphoma
12. Data from The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals
13. Supplementary Data from The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals
14. Supplementary Figure from The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals
15. Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation
16. Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and theGNA13mutant as poor prognostic biomarker, results of LNH‐EP1 study
17. RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies
18. Aberrant Proportion of Monocyte Subsets in Bone Marrow of High-Risk Myelodysplastic Syndrome Patients
19. Should Adolescents and Young Adults with Hodgkin Lymphoma be Treated As Children or Adults?
20. Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials
21. Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
22. Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study.
23. Sequence Analyses of Relapsed or Refractory Diffuse Large B-Cell Lymphomas Unravels Three Genetic Subgroups of Patients and GNA3 Mutant as Poor Prognosis Biomarker, Results of LNH-EP1 Study
24. BRAF V600E-induced senescence drives Langerhans cell histiocytosis pathophysiology
25. CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy
26. Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy
27. Thérapies cellulaires innovantes dans les tumeurs solides : CAR-T cells, TCR transgéniques, et autres produits : des premiers résultats intéressants mais encore beaucoup de recherche et de développement nécessaires !
28. Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH
29. Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma
30. Human Microbial Transplant Restores T Cell Cytotoxicity and Anti-Tumor Response to PD-L1 Blockade in Gnotobiotic Mice
31. Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH
32. Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)
33. A comprehensive analysis of Lymphoma-associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis
34. Characterizing hematopoietic precursors of Langerhans Cell Histiocytosis (LCH) using a humanized mouse model
35. RAF/MEK/extracellular signal–related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions
36. Hodgkin lymphoma in adolescent and young adults: insights from an adult tertiary single-center cohort of 349 patients
37. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
38. 1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis
39. Abstract A092: Comprehensive multidimensional analysis of the immune contexture in non-small cell lung cancer
40. Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
41. Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?
42. Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
43. Concurrent Radiation and ESHAP Regimen in Localized Extranodal NK/T-Cell Lymphoma Nasal Type, Phase II French Study
44. A Simple Scoring System for Identifying Relapsed/Refractory Lymphoma Patients Prematurely Withdrawn from Phase I Trials: The Gustave Roussy Experience
45. Treatment of Ovarian Anaplastic Ependymoma by an Aromatase Inhibitor
46. RAF/MEK/extracellular signal–related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions
47. [Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
48. BCL2 Inhibition Reveals a Dendritic Cell-Specific Immune Checkpoint That Controls Tumor Immunosurveillance.
49. The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.